Dilmapimodfeatured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:205999
CAS#:444606-18-2 (free base)
Description:Dilmapimod, also known as SB-681323 and GW-681323 , is p38 MAPK inhibitor. SB-681323 inhibited the p38 MAPK pathway to a greater degree than prednisolone did. SB-681323 inhibited TNF-alpha production. SB-681323 is a potent p38 MAPK inhibitor that potentially suppresses inflammation in COPD. The treatment with SB-681832 is a safe and effective means of reducing hsCRP in patients undergoing elective PCI.
Price and Availability
Dilmapimod, purity > 98%, is in stock.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 205999Name: DilmapimodCAS#: 444606-18-2 (free base)Chemical Formula: C23H19F3N4O3Exact Mass: 456.14093Molecular Weight: 456.42Elemental Analysis: C, 60.52; H, 4.20; F, 12.49; N, 12.28; O, 10.52
Related CAS #:937169-00-1 (tosylate)444606-18-2 (free base)
Synonym:SB681323; SB 681323; SB-681323; GW 681323; GW-681323; GW681323; Dilmapimod.
IUPAC/Chemical Name:8-(2,6-difluorophenyl)-2-((1,3-dihydroxypropan-2-yl)amino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7(8H)-one
InChi Key:ORVNHOYNEHYKJG-UHFFFAOYSA-N
InChi Code:InChI=1S/C23H19F3N4O3/c1-12-9-13(24)5-6-15(12)20-16-7-8-19(33)30(21-17(25)3-2-4-18(21)26)22(16)29-23(28-20)27-14(10-31)11-32/h2-9,14,31-32H,10-11H2,1H3,(H,27,28,29)
SMILES Code:O=C1C=CC2=C(C3=CC=C(F)C=C3C)N=C(NC(CO)CO)N=C2N1C4=C(F)C=CC=C4F
Technical Data
Additional Information
References
1: Betts JC, Mayer RJ, Tal-Singer R, Warnock L,Clayton C, Bates S, Hoffman BE, Larminie C, Singh D. Gene expressionchanges caused by the p38 MAPK inhibitor dilmapimod in COPD patients:analysis of blood and sputum samples from a randomized,placebo-controlled clinical trial. Pharmacol Res Perspect. 2015Feb;3(1):e00094. doi: 10.1002/prp2.94. Epub 2014 Dec 9. PubMed PMID:25692013; PubMed Central PMCID: PMC4317226.
我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是：建成全球最大的小分子抗癌药库 ，品种最多最全、质量最好最可靠。美帝药库的宗旨是：客户第一；质量第一；信誉第一；创新第一。
